Syantra

The company's core offering is the Syantra DX™ Breast Cancer test, a blood-based screening tool designed for the early detection of invasive breast cancer. This laboratory-developed test operates by measuring a panel of 12 gene expression biomarkers from a whole blood sample. The data is then interpreted by proprietary software that utilizes machine learning algorithms to produce a positive or negative result, indicating the presence or absence of a breast cancer signature. This molecular approach is designed to identify the most common types of invasive breast cancer in their initial stages when treatment is often more effective. The test is positioned as a supplemental tool to current imaging methods, particularly for women under 50 or those with dense breast tissue, where mammography can be less accurate.

Syantra operates on a private-pay model, with the test available through healthcare providers in Canada. Patients obtain a physician's requisition, provide a blood sample, which is then sent to Syantra's accredited laboratory for analysis. The results are returned to the requesting physician. The company has pursued commercialization by securing regulatory approvals, including CE marking for the European Union and accreditations for laboratories in the United States and Canada, with plans for global commercialization. Syantra has raised capital through funding rounds to scale its laboratory facilities, advance clinical studies, and expand its market presence.